• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach?

作者信息

Makarem Maisam, Leighl Natasha B

机构信息

Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.

出版信息

Cancer. 2020 Jul 15;126(14):3176-3180. doi: 10.1002/cncr.32875. Epub 2020 May 4.

DOI:10.1002/cncr.32875
PMID:32365225
Abstract
摘要

相似文献

1
Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach?肺腺癌的分子检测：是时候采用“血浆优先”方法了吗？
Cancer. 2020 Jul 15;126(14):3176-3180. doi: 10.1002/cncr.32875. Epub 2020 May 4.
2
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.循环游离核酸和血小板作为液体活检在肺癌患者个性化治疗中的应用
Lung Cancer. 2017 May;107:100-107. doi: 10.1016/j.lungcan.2016.04.026. Epub 2016 May 4.
3
Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.游离DNA与下一代测序助力肺癌个性化医疗
Oncotarget. 2016 Oct 25;7(43):71013-71035. doi: 10.18632/oncotarget.11717.
4
Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.通过表观基因组 cfDNA 分析检测晚期 EGFR 突变型肺腺癌患者中的小细胞转化。
Clin Cancer Res. 2024 Sep 3;30(17):3798-3811. doi: 10.1158/1078-0432.CCR-24-0466.
5
Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.非小细胞肺癌患者 NGS 液体活检分析的临床可行性。
PLoS One. 2019 Dec 20;14(12):e0226853. doi: 10.1371/journal.pone.0226853. eCollection 2019.
6
EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.晚期肺腺癌患者血浆游离 DNA 中的 EGFR 突变：液滴数字 PCR 可提高检测率
Target Oncol. 2019 Apr;14(2):197-203. doi: 10.1007/s11523-019-00623-x.
7
An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.液体活检在非小细胞肺癌诊断和监测应用中的研究进展。
Expert Rev Mol Diagn. 2018 Jan;18(1):35-45. doi: 10.1080/14737159.2018.1407243. Epub 2017 Nov 26.
8
Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.循环肿瘤DNA在胰腺癌分子评估和精准医学中的临床应用
Adv Exp Med Biol. 2016;924:13-17. doi: 10.1007/978-3-319-42044-8_3.
9
[Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].[不同治疗方法对肺腺癌循环游离DNA中表皮生长因子受体突变体的影响及预后]
Zhongguo Fei Ai Za Zhi. 2018 May 20;21(5):389-396. doi: 10.3779/j.issn.1009-3419.2018.05.06.
10
High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma.胸腔积液游离 DNA 高产量可用于诊断肺腺癌中的致癌基因突变。
Chest. 2023 Jul;164(1):252-261. doi: 10.1016/j.chest.2023.01.019. Epub 2023 Jan 21.

引用本文的文献

1
Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non-Small Cell Lung Cancer (LIQUIK).评估循环肿瘤DNA与循环肿瘤RNA联合液体活检在转移性非小细胞肺癌中的前瞻性多中心研究（LIQUIK）
JCO Precis Oncol. 2025 Jun;9:e2500181. doi: 10.1200/PO-25-00181. Epub 2025 Jun 26.
2
"Plasma-first" approach for molecular genotyping in non-small cell lung cancer: A narrative review.非小细胞肺癌分子基因分型的“血浆优先”方法：一篇叙述性综述
J Liq Biopsy. 2023 Oct 28;2:100123. doi: 10.1016/j.jlb.2023.100123. eCollection 2023 Dec.
3
Implementation of the clinical practice of liquid biopsies for thoracic oncology the experience of the RespirERA university hospital institute (Nice, France).
胸科肿瘤液体活检临床实践的实施：法国尼斯RespirERA大学医院研究所的经验
J Liq Biopsy. 2023 Aug 16;1:100004. doi: 10.1016/j.jlb.2023.100004. eCollection 2023 Sep.
4
Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC.组织和血浆联合下一代测序在初治晚期非小细胞肺癌患者中的临床应用
JTO Clin Res Rep. 2024 Dec 16;6(3):100778. doi: 10.1016/j.jtocrr.2024.100778. eCollection 2025 Mar.
5
Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives.肺癌的液体活检与组织活检：算法与展望
Cancers (Basel). 2024 Sep 29;16(19):3340. doi: 10.3390/cancers16193340.
6
Spectrum of Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma.晚期尿路上皮癌患者游离DNA的改变谱
Bladder Cancer. 2021 May 25;7(2):143-148. doi: 10.3233/BLC-201517. eCollection 2021.
7
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.在疑似晚期肺癌患者中，组织诊断前进行循环肿瘤 DNA 检测与治疗时间的关联：ACCELERATE 非随机临床试验。
JAMA Netw Open. 2023 Jul 3;6(7):e2325332. doi: 10.1001/jamanetworkopen.2023.25332.
8
Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach.晚期非小细胞肺癌患者的匹配组织活检和液体活检：一种可能不可或缺的补充方法。
Transl Oncol. 2023 Sep;35:101735. doi: 10.1016/j.tranon.2023.101735. Epub 2023 Jul 4.
9
Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.血浆优先：通过液体活检加速肺癌诊断和分子分析
Ther Adv Med Oncol. 2022 Sep 20;14:17588359221126151. doi: 10.1177/17588359221126151. eCollection 2022.
10
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.非小细胞肺癌中新靶向改变的检测优化的共识推荐建议。
Curr Oncol. 2022 Jul 15;29(7):4981-4997. doi: 10.3390/curroncol29070396.